The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation
The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation
复制标题
格拉斯哥预后评分作为同种异体造血细胞移植的移植前风险评估
DOI：
10.1111/ctr.13103
复制
发表时间：
2017
影响因子：
2.1
通讯作者：
Masuko Masayoshi
中科院分区：
文献类型：
--
作者：
Shibasaki Yasuhiko;Suwabe Tatsuya;Katagiri Takayuki;Tanaka Tomoyuki;Kobayashi Hironori;Fuse Kyoko;Ushiki Takashi;Sato Naoko;Yano Toshio;Kuroha Takashi;Hashimoto Shigeo;Narita Miwako;Furukawa Tatsuo;Sone Hirohito;Masuko Masayoshi
评估方法，如评分系统预测并发症的提前，是必要的，以确定异基因造血细胞移植（HCT）的适应性和选择适当的预处理方案。基于主要器官功能的造血细胞移植特异性合并症指数（HCT‐CI）是移植前风险评估的有用工具，已广泛应用于确定血液病患者的治疗策略。然而，由于同种异体HCT是在不同背景的患者中进行的，因此需要另一个加强HCT-CI的因素来评估移植前风险评估。据报告，评估C反应蛋白和白蛋白组合的格拉斯哥预后评分（GPS）可预测实体器官恶性肿瘤患者的生存期，与接受化疗/放疗和癌症分期无关。在本研究中，我们应用GPS对同种异基因HCT进行移植前风险评估。GPS成功地将患者分为总生存期（OS）和非复发死亡率（NRM）三个风险组。此外，在多变量分析中，GPS可以独立于HCT‐CI预测OS和NRM的结局。GPS被认为是一种有用的工具，并加强了HCT‐CI，以确定造血肿瘤患者的同种异体HCT适应性。
Evaluation methods, such as scoring systems for predicting complications in advance, are necessary for determining the adaptation of allogeneic hematopoietic cell transplantation (HCT) and selecting appropriate conditioning regimens. The Hematopoietic Cell Transplantation‐specific Comorbidity Index (HCT‐CI), which is based on functions of main organs, is a useful tool for pre‐transplant risk assessments and has been widely applied in determining treatment strategies for patients with hematological diseases. However, as allogeneic HCT is performed on patients with diverse backgrounds, another factor, which reinforces the HCT‐CI, is required to evaluate pre‐transplant risk assessments. The Glasgow Prognostic Score (GPS), which assesses the combined C‐reactive protein and albumin, was reported to predict survival of patients with solid‐organ malignancies independently of receiving chemo/radiotherapy and stages of cancer. In this study, we applied the GPS for pre‐transplant risk assessments for allogeneic HCT. The GPS successfully stratified the patients into three risk groups of overall survival (OS) and non‐relapse mortality (NRM). Moreover, the GPS could predict outcomes independently of the HCT‐CI for OS and NRM in multivariate analysis. The GPS is considered to be a useful tool and reinforces the HCT‐CI for determining adaptation of allogeneic HCT for patients with hematopoietic neoplasms.